Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8728431 | 0.86 | MGMT (0.46) | MGMTPNPPDE4APDE4BPDE4C | |
| SCHEMBL4963422 | 0.82 | PNP (0.40) | MGMTPNPPDE4APDE4BPDE4C | |
| SCHEMBL5084754 | 0.81 | MGMT (0.39) | MGMTPNP | |
| SCHEMBL4967495 | 0.80 | PNP (0.38) | MGMTPNPPDE4APDE4BPDE4C | |
| SCHEMBL4962859 | 0.80 | PDE4A (0.53) | MGMTPNPPDE4APDE4BPDE4C | |
| SCHEMBL3310277 | 0.79 | PNP (0.50) | PNPPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL18605981 | 0.79 | PDE4A (0.53) | MGMTPNPPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL17186468 | 0.78 | PNP (0.49) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21433943 | 0.78 | PNP (0.49) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2097440 | 0.78 | MGMT (0.47) | MGMTPNPDPP4PIN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| CN-1948313-A | Preparation method of tiemoazoleamine-8-carboxylic acid water soluble derivative, anticancer activity and application in preparing anticancer medicine | TIANJIN BEIFANG SCIENCE AND TE (CN) | 2007-04-18 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | claimed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | claimed |
| EP-4319773-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230339991-A1 | HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023150393-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11679121-B2 | Morpholino oligonucleotides useful in cancer treatment | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20210106608-A1 | Morpholino Oligonucleotides Useful In Cancer Treatment | OREGON HEALTH & SCIENCE UNIVERSITY | 2021-04-15 | — | — | US | disclosed |
| US-10857174-B2 | Morpholino oligonucleotides useful in cancer treatment | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2020-12-08 | — | — | US | disclosed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005068465-A1 | 2-AMINO-O4-SUBSTITUTED PTERIDINES AND THEIR USE AS INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1546370-A1 | PROTEIN LABELLING WITH O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031404-A1 | PROTEIN LABELLING WITH O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | MGMT 1/4885PNP 1267/4885PDE4A 2590/4885 |
| US-20230339991-A1 | HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF | HIF1AN, HIF1A, MGMT | MGMT 3/4885PNP 146/4885PDE4A 1354/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | MGMT 1/4885PNP 569/4885PDE4A 2657/4885 |
| US-10857174-B2 | Morpholino oligonucleotides useful in cancer treatment | MGMT, MSH2, DCLRE1B | MGMT 1/4885PNP 2147/4885PDE4A 3545/4885 |
| US-20210106608-A1 | Morpholino Oligonucleotides Useful In Cancer Treatment | MGMT, MSH2, DCLRE1B | MGMT 1/4885PNP 2147/4885PDE4A 3545/4885 |
| US-11679121-B2 | Morpholino oligonucleotides useful in cancer treatment | MGMT, MSH2, DCLRE1B | MGMT 1/4885PNP 2147/4885PDE4A 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.